PI3K/AKT/mTOR Pathway in Angiogenesis
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is activated in the majority of human cancers. This pathway is known to play a key role in numerous cellular functions including proliferation, adhesion, migration, invasion, metabolism, and survival, but in the current review we focus on its role in angiogenesis. PI3K activation may occur via RAS mutation, loss of phosphatase and tensin homolog (PTEN), or by increased expression of growth factor receptors such as epidermal growth factor receptor. There is a connection between the PI3K pathway and angiogenesis. Hypoxia leads to HIF-1α stabilization and is a major stimulus for increased vascular endothelial growth factor (VEGF) production by tumor cells. However, activation of the PI3K/AKT pathway in tumor cells can also increase VEGF secretion, both by hypoxia-inducible factor 1 (HIF-1) dependent and independent mechanisms. The PI3K/AKT pathway also modulates the expression of other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors targeting the PI3K/AKT/mTOR pathway have been developed, and these agents have been shown to decrease VEGF secretion and angiogenesis. The effect of these inhibitors on tumor vasculature can be difficult to predict. The vasculature of tumors is aberrant, leading to sluggish bloodflow and elevated interstitial blood pressure, which can be perpetuated by the high levels of VEGF. Hence, decreasing VEGF expression can paradoxically lead to vascular normalization and improved bloodflow in some tumors. In addition to its importance in cancer, the PI3K pathway also plays an essential role in the formation of normal blood vessels during development. Embryos with kinase-dead p110α catalytic subunit of PI3K develop vascular defects. Stimulation of endothelial cells by VEGF leads to activation of the PI3K pathway within these cells, which is important for cell migration. Sustained endothelial activation of AKT1 has been shown to induce the formation of structurally abnormal blood vessels that recapitulate the aberrations of tumor vessels. Hence, the PI3K pathway plays an important role in regulating angiogenesis both in normal tissues and in cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kasuno, K., Takabuchi, S., Fukuda, K., Kizaka-Kondoh, S., Yodoi, J., Adachi, T., Semenza, G. L., & Hirota, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308197200 · Cited by 226
RetractedTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 2×
“HIF-1α is upregulated across a broad range of cancers, and HIF regulates key features of tumor biology such as angiogenesis, invasion, and glucose metabolism (Ratcliffe et al., 2000; Semenza, 2003).”
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591 · cited 1×
“This regulation may occur via phosphorylation of eNOS at the serine 1177 residue by AKT (Dimmeler et al., 1999; Fulton et al., 1999).”
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
(1989) · PubMed · Cited by 3,343
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 3×
“The VEGF ligands can bind to three type III receptor tyrosine kinases: VEGFRl/FLT1, VEGFR2/KDR, and VEGFR3/FLT4, of which VEGFR2 has the most important role in VEGF-induced angiogenesis (Ellis and Hicklin, 2008).”
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Cited by
The intersection between aging and cardiovascular disease
North, B. J., & Sinclair, D. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.246876 · Cited by 1,585
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
Sever, R., & Brugge, J. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006098 · Cited by 989
NADPH Oxidases (NOX): An Overview from Discovery, Molecular Mechanisms to Physiology and Pathology
Vermot, A., Petit-Härtlein, I., Smith, S. M. E., & Fieschi, F. (2021) · Antioxidants · doi:10.3390/antiox10060890 · Cited by 766
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
The anti-cancer effect of quercetin: molecular implications in cancer metabolism
Reyes-Farias, M., & Carrasco-Pozo, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133177 · Cited by 689
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis
Abhinand, C. S., Raju, R., Soumya, S. J., Arya, P. S., & Sudhakaran, P. R. (2016) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-016-0352-8 · Cited by 502
Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
Wang, X., Bove, A. M., Simone, G., & Ma, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599281 · Cited by 442
Tao, S.-C., Guo, S.-C., Li, M., Ke, Q.-F., Guo, Y.-P., & Zhang, C.-Q. (2017) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0275 · Cited by 390
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
Chen, X., Duan, N., Zhang, C., & Zhang, W. (2016) · Journal of Cancer · doi:10.7150/jca.13332 · Cited by 347
Role of the tumor microenvironment in tumor progression and the clinical applications (Review)
YUAN, Y., JIANG, Y.-C., SUN, C.-K., & CHEN, Q.-M. (2016) · Oncology Reports · doi:10.3892/or.2016.4660 · Cited by 320
Role of Phytochemicals in Cancer Chemoprevention: Insights
George, B. P., Chandran, R., & Abrahamse, H. (2021) · Antioxidants · doi:10.3390/antiox10091455 · Cited by 295
Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma
Nikbakht, H., Panditharatna, E., Mikael, L. G., Li, R., Gayden, T., Osmond, M., Ho, C.-Y., Kambhampati, M., Hwang, E. I., Faury, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11185 · Cited by 252
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression
Xue, C., Li, G., Lu, J., & Li, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00788-w · Cited by 268
Mechanisms of lncRNA/microRNA interactions in angiogenesis
Zhao, Z., Sun, W., Guo, Z., Zhang, J., Yu, H., & Liu, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.116900 · Cited by 262
Regulation of Akt Signaling by Sirtuins: Its Implication in Cardiac Hypertrophy and Aging
Pillai, V. B., Sundaresan, N. R., & Gupta, M. P. (2014) · Circulation Research · doi:10.1161/circresaha.113.300536 · Cited by 261
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Wang, J., Man, G. C. W., Chan, T. H., Kwong, J., & Wang, C. C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.09.054 · Cited by 127
Jung, K. B., Lee, H., Son, Y. S., Lee, M.-O., Kim, Y.-D., Oh, S. J., Kwon, O., Cho, S., Cho, H.-S., Kim, D.-S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05450-8 · Cited by 125
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Combination of nanotechnology with vascular targeting agents for effective cancer therapy
Jahanban‐Esfahlan, R., Seidi, K., Banimohamad‐Shotorbani, B., Jahanban‐Esfahlan, A., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26051 · Cited by 84
Foster, P., Yamaguchi, K., Hsu, P. P., Qian, F., Du, X., Wu, J., Won, K.-A., Yu, P., Jaeger, C. T., Zhang, W., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0833 · Cited by 58
Li, Y., Pasunooti, K. K., Li, R.-J., Liu, W., Head, S. A., Shi, W. Q., & Liu, J. O. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01252 · Cited by 43
Lei, Z., Mozaffaritabar, S., Kawamura, T., Koike, A., Kolonics, A., Kéringer, J., Pinho, R. A., Sun, J., Shangguan, R., & Radák, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24421 · Cited by 36
Shi, J., Lv, H., Tang, C., Li, Y., Huang, J., & Zhang, H. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12112 · Cited by 34
Mathews Samuel, S., Satheesh, N. J., Ghosh, S., Büsselberg, D., Majeed, Y., Ding, H., & Triggle, C. R. (2019) · Cancers · doi:10.3390/cancers11111737 · Cited by 28
Karavasilis, V., Samantas, E., Koliou, G.-A., Kalogera-Fountzila, A., Pentheroudakis, G., Varthalitis, I., Linardou, H., Rallis, G., Skondra, M., Papadopoulos, G., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0605-y · Cited by 27
Metadata
- Authors
- Karar, J., & Maity, A.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2011
- Volume
- 4
- Pages
- 51-51
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2014087704
- Cited by
- 1,461
- References
- 101
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.